Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 16/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 15/20 | 0.67 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.55 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.54 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.54 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26843366 | 0.91 | ITGB3 (0.66) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL6426136 | 0.90 | ITGAV (0.71) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL7377654 | 0.89 | ITGAV (0.69) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL13720083 | 0.86 | ITGAV (0.69) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL3219843 | 0.86 | ITGAV (0.65) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL3219507 | 0.85 | ITGAV (0.64) | ITGAVITGB3CXCR4ITGB6 | |
| SCHEMBL22893669 | 0.85 | ITGAV (0.61) | ITGAVITGB3CXCR4ITGB6 | |
| SCHEMBL21329736 | 0.85 | ITGAV (0.60) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL22910283 | 0.84 | ITGAV (0.56) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL29416356 | 0.84 | ITGAV (0.66) | ITGAVITGB3ITGB6ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817294-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | Amgen Inc. (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006019975-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | AMGEN INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | ITGB6, ITGA5, ITGAV | ITGAV 3/4885ITGB3 9/4885CXCR4 631/4885 |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | ITGB6, ITGAV, ITGA6 | ITGAV 2/4885ITGB3 13/4885CXCR4 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.